Dr Christos Rossios is a Research Associate in the Molecular Cell Biology Group within the Airway Disease Section of the National Heart and Lung Institute. He also holds an horonary research position at the Royal Brompton and Harefield NHS Trust.
Christos studied Biochemistry/Microbiology as an undergraduate at Queen Mary, University of London. He then he undertook an MSc in Molecular Life Sciences Research at King’s College London. Following the completion of his MSc he remained at King’s College London as a research assistant in Dr. Malik’s Diabetes Research Group. During his time at King’s College London, he has been interested in candidate diabetes-associated kidney genes and their involvement in diabetic nephropathy.
In 2005, Christos joined the National Heart and Lung Institute as an academic visitor in Dr. Kazuhiro Ito’s research group where he investigated the regulation of SIRT1 expression and activity under oxidative stress. In the same year he enrolled for a PhD programme under the supervision of Dr. Kazuhiro Ito, studying the effect of combination therapy of a long-acting β2 agonist and a corticosteroid in Chronic Obstructive Pulmonary Disease (COPD), taking a molecular and pharmacological approach.
Following the completion of his PhD studies, Christos joined Prof. Ian Adcock’s group as a research associate. He is part of U-BIOPRED, a 39 international partner IMI consortium, concerned with the discovery of unbiased biomarkers for the prediction of respiratory diseases, especially severe asthma. Christos is particularly interested in the effect of several innate immune response mediators on inflammation and corticosteroid sensitivity in airway smooth muscle cells and primary epithelial cells isolated from endobronchial biopsies or bronchial brushings, respectively.
The main focus of Christos’s research lies within the innate immune response and the role of corticosteroid function in severe asthma. Christos has presented his work at several international meetings and in peer-reviewed journals.
et al., 2023, Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study., The Lancet Respiratory Medicine, Vol:11, ISSN:2213-2600, Pages:55-64
et al., 2022, Leucine and perindopril to improve physical performance in people over 70 years with sarcopenia: the LACE factorial RCT, Efficacy and Mechanism Evaluation, Vol:9, ISSN:2050-4365, Pages:1-82
et al., 2022, Clinical and transcriptomic features of persistent exacerbation-prone severe asthma in U-BIOPRED cohort, Clinical and Translational Medicine, Vol:12, ISSN:2001-1326
et al., 2022, Effect of Perindopril or Leucine on physical performance in older people with sarcopenia: the LACE randomised controlled trial, Journal of Cachexia, Sarcopenia and Muscle, Vol:13, ISSN:2190-6009, Pages:858-871
et al., 2022, Association of Differential Mast Cell Activation with Granulocytic Inflammation in Severe Asthma, American Journal of Respiratory and Critical Care Medicine, Vol:205, ISSN:1073-449X, Pages:397-+